drugset
drugset / Trial / NCT05981235

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

NCT05981235 ↗

Phase 1 Completed 8 enrolled Peking University AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

Timeline

Start
2023-12-14
Primary completion
2025-06-25
Completion
2025-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6422 Cell therapy — Other

Indications

digestive system neoplasm